NZ511760A - Methods for the production of TcR gamma delta T cells - Google Patents
Methods for the production of TcR gamma delta T cellsInfo
- Publication number
- NZ511760A NZ511760A NZ511760A NZ51176099A NZ511760A NZ 511760 A NZ511760 A NZ 511760A NZ 511760 A NZ511760 A NZ 511760A NZ 51176099 A NZ51176099 A NZ 51176099A NZ 511760 A NZ511760 A NZ 511760A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- present
- amount
- tcry8
- culture medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 title description 2
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 title description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 206
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 189
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 103
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 103
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract description 96
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 96
- 229940028885 interleukin-4 Drugs 0.000 claims abstract description 88
- 239000001963 growth medium Substances 0.000 claims abstract description 59
- 238000012258 culturing Methods 0.000 claims abstract description 32
- 239000003226 mitogen Substances 0.000 claims abstract description 31
- 239000003636 conditioned culture medium Substances 0.000 claims abstract description 13
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 108010062580 Concanavalin A Proteins 0.000 claims description 35
- 210000005259 peripheral blood Anatomy 0.000 claims description 20
- 239000011886 peripheral blood Substances 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 18
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 17
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 15
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 14
- 210000005087 mononuclear cell Anatomy 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 102100035716 Glycophorin-A Human genes 0.000 claims description 5
- 108091005250 Glycophorins Proteins 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 20
- 108090000695 Cytokines Proteins 0.000 abstract description 20
- 239000002609 medium Substances 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000002243 precursor Substances 0.000 abstract description 2
- 239000012636 effector Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004748 cultured cell Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 6
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- -1 AIM-VTM Substances 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 108010089814 Plant Lectins Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000003726 plant lectin Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- MQCJHQBRIPSIKA-UHFFFAOYSA-N prenyl phosphate Chemical compound CC(C)=CCOP(O)(O)=O MQCJHQBRIPSIKA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/59—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10700698P | 1998-11-04 | 1998-11-04 | |
| PCT/CA1999/001024 WO2000026347A1 (en) | 1998-11-04 | 1999-11-04 | Methods for the production of tcr gamma delta t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ511760A true NZ511760A (en) | 2003-10-31 |
Family
ID=22314363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ511760A NZ511760A (en) | 1998-11-04 | 1999-11-04 | Methods for the production of TcR gamma delta T cells |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6537812B1 (https=) |
| EP (1) | EP1127107B1 (https=) |
| JP (1) | JP4435985B2 (https=) |
| AT (1) | ATE421573T1 (https=) |
| AU (1) | AU759373B2 (https=) |
| CA (1) | CA2349629C (https=) |
| DE (1) | DE69940352D1 (https=) |
| ES (1) | ES2319942T3 (https=) |
| NZ (1) | NZ511760A (https=) |
| WO (1) | WO2000026347A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE449162T1 (de) * | 2000-04-03 | 2009-12-15 | Therapure Biopharma Inc | Herstellung von tcr gamma delta t-zellen |
| US20030157060A1 (en) * | 2000-04-03 | 2003-08-21 | Bell David N | Production of tcr gamma delta t cells |
| EP1778836B1 (en) * | 2004-08-19 | 2010-08-04 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy |
| CN101313061B (zh) | 2005-11-18 | 2013-05-15 | 大学健康网络 | 扩增双阴性t细胞的方法 |
| CA2659697A1 (en) | 2006-08-01 | 2008-02-07 | Arigen Pharmaceuticals, Inc. | Method of proliferating lak cell |
| GB201421716D0 (en) * | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| KR102663157B1 (ko) | 2015-06-09 | 2024-05-13 | 감마델타 테라퓨틱스 엘티디 | Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법 |
| AU2016274633B2 (en) * | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP4148124A1 (en) | 2015-10-30 | 2023-03-15 | Cancer Research Technology Limited | Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| KR20210111746A (ko) * | 2018-11-08 | 2021-09-13 | 감마델타 테라퓨틱스 리미티드 | 세포를 단리 및 증식하는 방법 |
| EP4198120A4 (en) * | 2020-08-14 | 2024-05-08 | Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd | METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND THEIR USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639653A (en) * | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
| US5877299A (en) * | 1995-06-16 | 1999-03-02 | Stemcell Technologies Inc. | Methods for preparing enriched human hematopoietic cell preparations |
| CA2275141A1 (en) * | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
| WO1998033891A1 (en) * | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| WO1999046365A1 (en) | 1998-03-12 | 1999-09-16 | Emory University | Methods and compositions for the selective expansion of gamma/delta t-cells |
-
1999
- 1999-11-04 US US09/807,987 patent/US6537812B1/en not_active Expired - Lifetime
- 1999-11-04 AT AT99953463T patent/ATE421573T1/de not_active IP Right Cessation
- 1999-11-04 WO PCT/CA1999/001024 patent/WO2000026347A1/en not_active Ceased
- 1999-11-04 DE DE69940352T patent/DE69940352D1/de not_active Expired - Lifetime
- 1999-11-04 JP JP2000579719A patent/JP4435985B2/ja not_active Expired - Fee Related
- 1999-11-04 NZ NZ511760A patent/NZ511760A/en unknown
- 1999-11-04 ES ES99953463T patent/ES2319942T3/es not_active Expired - Lifetime
- 1999-11-04 AU AU10219/00A patent/AU759373B2/en not_active Ceased
- 1999-11-04 CA CA2349629A patent/CA2349629C/en not_active Expired - Fee Related
- 1999-11-04 EP EP99953463A patent/EP1127107B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000026347A1 (en) | 2000-05-11 |
| JP4435985B2 (ja) | 2010-03-24 |
| DE69940352D1 (de) | 2009-03-12 |
| CA2349629A1 (en) | 2000-05-11 |
| AU1021900A (en) | 2000-05-22 |
| AU759373B2 (en) | 2003-04-10 |
| ES2319942T3 (es) | 2009-05-14 |
| EP1127107B1 (en) | 2009-01-21 |
| US6537812B1 (en) | 2003-03-25 |
| ATE421573T1 (de) | 2009-02-15 |
| CA2349629C (en) | 2010-01-26 |
| JP2002528115A (ja) | 2002-09-03 |
| EP1127107A1 (en) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250152630A1 (en) | Methods for the production of tcr gamma delta + t cells | |
| Dowell et al. | Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12 | |
| US12173319B2 (en) | Methods for the production of TCR gamma delta + T cells | |
| US11473059B2 (en) | Method for enrichment and expansion of virus antigen-specific T cells | |
| CA2349629C (en) | Methods for the production of tcr gamma delta t cells | |
| CA2629532C (en) | Method of expanding double negative t cells | |
| Peragine et al. | Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients | |
| CA2405050C (en) | Production of tcr gamma delta t cells | |
| US20030194395A1 (en) | Th1 cell adoptive immunotherapy | |
| AU2001248162A1 (en) | Production of TcR gamma delta T cells | |
| Takahashi et al. | Dendritic cells generated from human blood in granulocyte macrophage-colony stimulating factor and interleukin-7 | |
| Lehner et al. | Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions | |
| US20030157060A1 (en) | Production of tcr gamma delta t cells | |
| Ye et al. | In vitro interactions between γδT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia | |
| Schilling et al. | IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model | |
| Recktenwald | CELLS RELEASED FROM THE IMMUNOAFFINITY DEVICE: NO RESIDUAL MOUSE IMMUNOGLOBULIN | |
| HK1245831B (en) | Methods for the production of tcr gamma delta+ t cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |